Abstract
Molecular measurable residual disease can persist in core-binding factor acute myeloid leukemia in otherwise disease-free patients. Utilizing cell sorting followed by fluorescent in situ hybridization, we show that detection is due to mast cells.
© 2024 American Society of Hematology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
MeSH terms
-
Core Binding Factor Alpha 2 Subunit / genetics
-
Core Binding Factor Alpha 2 Subunit / metabolism
-
Female
-
Flow Cytometry* / methods
-
Humans
-
In Situ Hybridization, Fluorescence
-
Leukemia, Myeloid, Acute* / diagnosis
-
Leukemia, Myeloid, Acute* / genetics
-
Leukemia, Myeloid, Acute* / metabolism
-
Leukemia, Myeloid, Acute* / pathology
-
Male
-
Mast Cells* / metabolism
-
Mast Cells* / pathology
-
Neoplasm, Residual* / diagnosis
-
Oncogene Proteins, Fusion* / genetics
-
Oncogene Proteins, Fusion* / metabolism
-
RUNX1 Translocation Partner 1 Protein / genetics
-
RUNX1 Translocation Partner 1 Protein / metabolism
Substances
-
Oncogene Proteins, Fusion
-
RUNX1 Translocation Partner 1 Protein
-
Core Binding Factor Alpha 2 Subunit